Nanomerics’ CSO made a Dame Commander in the UK New Year’s 2025 Honours

Nanomerics Ltd., a private speciality pharmaceutical company today announced that its Chief Scientific Officer, Professor Ijeoma F. Uchegbu has been made a Dame Commander of the Order of the British Empire (DBE) in the UK New Year 's 2025 Honours list. Uchegbu was awarded a DBE "for services to the chemical sciences and to diversity and inclusion".

LONDON, UNITED KINGDOM / ACCESSWIRE / December 30, 2024 /The DBE is a senior rank of the Order of the British Empire and is one of the highest honours that may be awarded to a woman in the UK. A DBE is awarded for a pre-eminent contribution in any field of activity (usually, but not exclusively, at national level), or in a capacity which will be recognized by peer groups as inspirational and significant nationally and demonstrates sustained commitment.

Uchegbu has spent all of her professional life working in the chemical sciences and is credited with designing multiple drug delivery systems; the most conspicuous of which is Nanomerics ' Molecular Envelope Technology (MET), a novel excipient, designed and synthesized in UK academic laboratories. Nanomerics ' lead pharmaceutical asset, OC134 eye drops, is powered by Nanomerics ' MET, which is a non-irritant ocular penetration enhancer. Nanomerics ' MET has been shown in preclinical studies to increase the penetration of active pharmaceutical ingredients (APIs) into the front of the eye; increasing ocular deposition up to 18-fold, when compared to conventional formulations. In these preclinical studies, Nanomerics ' MET also demonstrated the delivery of active pharmaceutical ingredients (APIs) to the retina from eye drops.

In a significant milestone, human dosing of OC134 recently commenced in the SUNLIGHT trial. Nanomerics has a pipeline of ocular assets that may now be tested in clinical studies and ultimately launched for the benefit of patients.

Professor Ijeoma F. Uchegbu, Nanomerics ' Chief Scientific Officer

"I am incredibly thrilled to have been awarded this honour. I am so grateful that colleagues felt that I was worthy of this recognition. It is a moment of immense pride for me and for Nanomerics as it recognizes our decades long work aimed at creating efficacious medicines with reduced side effects."

Nanomerics ' MET is being used to formulate other eye drops such as: OC137, indicated for the treatment of dry age-related macular degeneration (dry AMD) and OC135, indicated for the treatment of glaucoma. Nanomerics is based in state-of-the-art laboratories in North London.

For press enquiries contact:

Pedro Margarido
Head of Operations, Nanomerics Ltd.
pedro.margarido@nanomerics.com

About Nanomerics

Nanomerics Ltd is a specialty pharmaceutical company based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics ' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company 's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis and OC137 for the treatment of retinal diseases. For more information, please visit www.nanomerics.com

About the British Honours System

The British honours system rewards individuals with Honours, Decorations and Medals in public recognition of their merit, service or bravery. Honours are announced and awarded twice a year by His Majesty The King, with lists consisting of knights and dames, appointments to the Order of the British Empire, and gallantry and bravery awards. Different awards are received depending on an individual 's achievements.

What is the Order of the British Empire?

Perhaps the most well-known awards are classes of appointment to the Order of the British Empire. Instituted in 1917 by George V, the awards were created during World War I to reward services to the war effort by people not on the front line. However, they are now appointed to civilians as well as members of the armed forces.

They include (in order of precedence):

• GBE (Knight or Dame) - Knight Grand Cross or Dame Grand Cross of the Most Excellent Order of the British Empire

• KBE or DBE (Knight or Dame) - Knight Commander or Dame Commander of the Most Excellent Order of the British Empire

• CBE - Commander of the Most Excellent Order of the British Empire

• OBE - Officer of the Most Excellent Order of the British Empire

• MBE - Member of the Most Excellent Order of the British Empire

The two senior ranks of the Order of the British Empire are Knight or Dame Grand Cross, and Knight or Dame Commander. Both of these ranks entitle their members to use the title of Sir for men and Dame for women before their forename.

The honour is appointed to members who have made major contributions to any activity, usually at national level. Per tradition, knighthoods are often presented with a touch of a sword by the King or Queen.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management 's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law.

SOURCE:Nanomerics Ltd

View the original press release on accesswire.com

© 2024 Accesswire. All Rights Reserved.